Harvard Bioscience (HBIO) Non-Current Deferred Tax Liability (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Non-Current Deferred Tax Liability of $313000.0 for Q1 2026, down 56.35% year-over-year from $717000.0 in Q1 2025, and down 1.26% quarter-over-quarter from $317000.0 in Q4 2025.
Harvard Bioscience (HBIO) Non-Current Deferred Tax Liability (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Non-Current Deferred Tax Liability for 17 consecutive years, with $313000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 56.35% year-over-year to $313000.0; the TTM figure through Mar 2026 stood at $313000.0 (down 56.35% YoY), while the FY2025 annual figure was $317000.0, down 55.35% from the prior year.
- Non-Current Deferred Tax Liability declined to $313000.0 in Q1 2026 per HBIO's latest filing, from $317000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $2.4 million in Q2 2022 and bottomed at $313000.0 in Q1 2026.
- Historically, Non-Current Deferred Tax Liability has averaged $826882.4 across 5 years, with a median of $717000.0 in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability jumped 54.39% — and 2023, when it tumbled 72.52%.
- Harvard Bioscience's Non-Current Deferred Tax Liability stood at $590000.0 in 2022, then surged by 31.53% to $776000.0 in 2023, then decreased by 8.51% to $710000.0 in 2024, then sank by 55.35% to $317000.0 in 2025, then decreased by 1.26% to $313000.0 in 2026.
- Business Quant data shows HBIO's Non-Current Deferred Tax Liability at $313000.0 in Q1 2026, $317000.0 in Q4 2025, and $733000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 311,000.00 |
| Jun 30, 2026 | 311,000.00 |
| Mar 31, 2026 | 313,000.00 |
| Mar 31, 2026 | 313,000.00 |
| Dec 31, 2025 | 317,000.00 |
| Dec 31, 2025 | 317,000.00 |
| Sep 30, 2025 | 733,000.00 |
| Sep 30, 2025 | 733,000.00 |
| Jun 30, 2025 | 734,000.00 |
| Jun 30, 2025 | 734,000.00 |
| Mar 31, 2025 | 717,000.00 |
| Mar 31, 2025 | 717,000.00 |
| Dec 31, 2024 | 710,000.00 |
| Dec 31, 2024 | 710,000.00 |
| Sep 30, 2024 | 707,000.00 |
| Sep 30, 2024 | 707,000.00 |
| Jun 30, 2024 | 764,000.00 |
| Jun 30, 2024 | 764,000.00 |
| Mar 31, 2024 | 772,000.00 |
| Mar 31, 2024 | 772,000.00 |